The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer
S. Cheng, N. Prieto-Dominguez, S. Yang, Z. Connelly, S. StPierre, B. Rushing, A. Watkins, L. Shi, M. Lakey, L. Baiamonte, T. Fazili, A. Lurie, E. Corey, R. Shi, Y. Yeh, X. Yu
This study shows YAP1 is increased in high-grade prostate adenocarcinoma but reduced in neuroendocrine prostate cancer, with YAP1 loss activating Wnt/beta-Catenin signaling linked to NEPC development.
bioRxiv · Nov 6, 2019Cancer Biology